Q-omics provides the consensus-scored NEK3 profile across patient tissues and cancer cell-line models. NEK3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NEK3 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, NEK3 RNA expression shows 19,961 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where NEK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEK3 survival associations across molecular data types. NEK3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEK3 RNA expression–survival associations across cancer types. High NEK3 expression shows unfavorable associations in ACC, CESC, KICH, UVM and LGG, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NEK3 RNA expression.
This table summarizes NEK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for NEK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEK3 shows lower tumor expression in KICH, LUSC and BRCA and higher tumor expression in STAD, COAD and HNSC. The KICH box plot shows higher NEK3 RNA expression in normal versus tumor tissue (log2 FC = −1.456, t-test p < 0.001).
This table shows molecular features associated with NEK3 in patient tissues and cancer cell lines. In patient samples, NEK3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NEK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
